DocumentoFormal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants November 2015 Procedural 15085fnlcargado por
Markbot1999- DocumentoBioeqivalence Recommendations for Specific Products 8857fnl.pdfcargado porMarkbot1999
- DocumentoWaiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System DRAFT May 2015 Rev 1 ucm070246.pdfcargado porMarkbot1999
- DocumentoBioeqivalence Recommendations for Specific Products 8857fnlcargado porMarkbot1999
- DocumentoWaiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System DRAFT May 2015 Rev 1 ucm070246.pdfcargado porMarkbot1999
- DocumentoDesignation of Official Names and Proper Names for Certain Biological Products Propose Rule 2015-21382cargado porMarkbot1999
- DocumentoMAPP 5240.3 Rev.2 Prioritization of the Review of Original ANDAs, Amendments, and Supplements.pdfcargado porMarkbot1999
- DocumentoOff-Patent Off-Exclusivity Drug List with no Generic 2017-10-30.pdfcargado porMarkbot1999
- DocumentoUpdating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn July 2016 Generics 3048879dft.pdfcargado porMarkbot1999
- DocumentoReferencing Approved Drug Products in ANDA Submissions DRAFT 01-2017 Generics.pdfcargado porMarkbot1999
- DocumentoInspections and ANDA Review CDER OC OMQ’s Role Francis Godwin OMQ CDER GPhA Fall 2016cargado porMarkbot1999
- DocumentoGood ANDA Submission Practices DRAFT January 2018 Generics.pdfcargado porMarkbot1999
- DocumentoStability Guidance & Draft Q&A Guidance considerations FDA Small Business WEBINAR 2013-11-04 UCM373234.pdfcargado porMarkbot1999
- DocumentoRLD - reference standard - BOS draft guidance webinar 1-18-17.pdfcargado porMarkbot1999
- DocumentoGood Abbreviated New Drug Application Assessment Practices MAPP 5241.3 2018-01-03cargado porMarkbot1999
- DocumentoGood ANDA Submission Practices DRAFT January 2018 Generics.pdfcargado porMarkbot1999
- DocumentoControlled Correspondence Related to Generic Drug Development September 2015 Generics.pdfcargado porMarkbot1999
- DocumentoAssessing Adhesion with Transdermal Delivery Systems and Topical Patches for ANDAs Draft June 2016 Generic Drugs.pdfcargado porMarkbot1999
- DocumentoANDAs Stability Testing of Drug Substances and Products Questions and Answers May 2014 Generics CDER2013213 guidance May2.pdfcargado porMarkbot1999
- DocumentoANDA Submissions Refuse-to-Receive Standards Guidance for Industry May 2015 Generic Drugs Revision 1.pdfcargado porMarkbot1999
- DocumentoANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA July 2014 Generic Drugs DRAFT.pdfcargado porMarkbot1999
- DocumentoANDA Submissions Refuse-to-Receive Standards December 2016 Generics Revision 2.pdfcargado porMarkbot1999
- DocumentoANDA Submissions Refuse to Receive for Lack of Justification of Impurity Limits 20160810.pdfcargado porMarkbot1999
- DocumentoANDAs Stability Testing of Drug Substances and Products June 2013 Generics 10956fnl ANDAs_ 5-6-2013 CLEAN.pdfcargado porMarkbot1999
- DocumentoANDA Submissions Prior Approval Supplements Under GDUFA October 2016 Genericscargado porMarkbot1999
- DocumentoProviding Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs DRAFT April 2015cargado porMarkbot1999
- DocumentoCommunications With Industry With Respect to Pre-GDUFA Year Three ANDAs MAPP 5200.3 Rev. 1cargado porMarkbot1999
- DocumentoWebinar - Amendments and Easily Correctable Deficiencies Under GDUFA 063014cargado porMarkbot1999
- DocumentoANDA Submissions Prior Approval Supplements Under GDUFA DRAFT July 2014 16479dft_07-09-14.pdfcargado porMarkbot1999
- DocumentoSelf-Identification of Generic Drug Facilities Sites and Organizations September 2016 Generics GDUFA Self ID Final Guidance2cargado porMarkbot1999
- DocumentoANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA July 2014 16478dft_07-09-14.pdfcargado porMarkbot1999
- DocumentoDay2.4 - Mozzachio - Post-Approval and Surveillance Inspectioncargado porMarkbot1999
- DocumentoDay2.2 - Lionberger - GDUFA Regulatory Sciencecargado porMarkbot1999
- DocumentoDay1.6 - Zhang - DMFs With a GDUFA Perspectivecargado porMarkbot1999
- DocumentoDay1.7 - Song - Completeness Assessment for TYpe II API DMF Under GDUFAcargado porMarkbot1999
- DocumentoDay1.5 - Shaw - Drug Master File (DMF) Basicscargado porMarkbot1999
- DocumentoDay1.4 - Lantzy - Optimizing Your eCTD ANDAcargado porMarkbot1999
- DocumentoDay1.3 - Lee - A Filing Reviewer's Perspectivecargado porMarkbot1999
- DocumentoDay1.2 - Young - An Overview of the Draft Guidance for Industry - ANDA Submissions RTRcargado porMarkbot1999
- DocumentoDay2.6 - Park - GDUFA Review Efficiency Enhancementscargado porMarkbot1999
- DocumentoFDA Perspectives - Scientific Considerations of Forced Degradation Studies in ANDA Submissions Ragine Maheswaran MAY 2012cargado porMarkbot1999
- DocumentoProcess Validation General Principles and Practices January 2011 Revision 1 9365fnlcargado porMarkbot1999
- Documento- 879 CHAPTER 64E-16 BIOMEDICAL WASTEcargado porMarkbot1999
- DocumentoVitamin B New Researchcargado porMarkbot1999
Documentos de Académico
Documentos de Profesional
Documentos de Cultura
